• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Tiered Serological and Multiplex PCR Protocol Improves Sleeping Sickness Screening in Low-Prevalence Settings

by
November 19, 2026
in Health
Reading Time: 6 mins read
0
Tiered Serological and Multiplex PCR Protocol Improves Sleeping Sickness Screening in Low-Prevalence Settings

Tiered Serological and Multiplex PCR Protocol Improves Sleeping Sickness Screening in Low-Prevalence Settings

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers at the University of Nigeria have introduced a stratified diagnostic protocol that combines sequential serological screening with targeted multiplex polymerase chain reaction testing to detect human African trypanosomiasis in low-resource and low-prevalence environments. Human African trypanosomiasis, widely known as sleeping sickness, is a neglected tropical disease caused by protozoan parasites of the Trypanosoma brucei species. In Africa, two distinct subspecies are responsible for disease in humans: Trypanosoma brucei gambiense, which accounts for ninety-two percent of the global disease burden and is targeted by the World Health Organization for elimination by 2030, and Trypanosoma brucei rhodesiense. As endemic regions achieve substantial progress through strengthened vector control strategies, active surveillance, and improved case management programs, transmission rates drop, leaving health systems with the complex operational task of detecting rare infections characterized by low prevalence and low parasitemia.

Standard parasitological microscopy remains the historical gold standard for definitive confirmation of sleeping sickness, but it frequently lacks sufficient sensitivity when parasite densities in blood are low. The gambiense form of the disease typically manifests with very low parasitemia, and despite the application of physical concentration techniques, routine microscopic community screening is both labor-intensive and time-consuming. Clinical diagnosis presents further difficulties because early symptoms are often unspecific, and asymptomatic or silent carriers can persist within populations, potentially maintaining transmission cycles unnoticed. While serological tests such as the card agglutination test for trypanosomiasis and enzyme-linked immunosorbent assays provide higher throughput and enhanced sensitivity for large-scale field screening, standalone antibody detection cannot reliably differentiate between active infection and past exposure. Persisting circulating antibodies from successfully treated historical infections or cross-reactions triggered by co-endemic protozoa like malaria can yield false-positive results, complicating surveillance decisions.

To overcome these limitations without placing impossible financial and logistical burdens on local laboratories, the authors developed a tiered diagnostic framework that sequences serological assays prior to molecular intervention. Under this system, broad population screening is performed using relatively low-cost serological methods, reserving downstream molecular assays exclusively for samples that test positive on antibody screens. This selective structure reduces the overall volume of specimens requiring molecular testing, thereby avoiding the prohibitive expenses and reagent demands associated with applying nucleic acid amplification across an entire screened community. The workflow integrates an initial enzyme-linked immunosorbent assay, a secondary card agglutination test for trypanosomiasis, and a dual-target multiplex polymerase chain reaction step designed to provide clear molecular confirmation of parasite DNA.

The procedural framework begins with field collection of one milliliter of human venous blood taken aseptically into tubes containing ethylenediaminetetraacetic acid. Samples are packed into coolers with ice packs and transported promptly to the testing facility, where each specimen is divided into two aliquots. One aliquot is processed to separate serum or plasma for serological analysis, while the remaining whole blood is reserved for molecular investigation. If immediate laboratory processing cannot occur, the protocol specifies storing serum samples under refrigeration at four degrees Celsius and freezing the whole blood aliquot at minus twenty degrees Celsius until genomic DNA extraction can take place.

Initial serological screening relies on an enzyme-linked immunosorbent assay configured to identify anti-trypanosome antibodies across large batches of specimens. In the absence of commercial microplate kits, the protocol details preparing antigen by harvesting in vitro cultures of Trypanosoma brucei gambiense at a density of one million cells per milliliter, washing the parasites in one-times phosphate-buffered saline, and using whole parasite suspensions or detergent-lysed soluble antigens diluted one to one hundred in carbonate coating buffer. Microtiter plates are blocked with two percent casein in phosphate-buffered saline for ninety minutes at room temperature, followed by incubation with patient serum diluted one to two hundred in one percent casein. Detection is carried out using horseradish peroxidase-conjugated anti-human immunoglobulin G secondary antibodies and twenty-two-azino-bis-three-ethylbenzothiazoline-six-sulfonic acid substrate, with optical density measured on a spectrophotometer at four hundred and five nanometers and normalized against negative control values plus three standard deviations.

Specimens that yield seropositive results on the initial enzyme-linked immunosorbent assay immediately proceed to a second serological filter using the card agglutination test for trypanosomiasis, known as CATT. Evaluating positive samples with CATT at a serum dilution of one to four improves overall serological specificity while avoiding false negatives that might arise from cross-reactions. Samples exhibiting clear agglutination are classified as positive, whereas ambiguous or equivocal results are reassessed to ensure that only unambiguously reactive specimens advance to downstream molecular evaluation. By pairing these two serological tools sequentially, the protocol filters out non-specific background reactions before any high-cost molecular reagents are consumed.

Samples confirming seropositivity across both screening assays are subsequently subjected to molecular testing using whole blood aliquots. Genomic DNA is extracted from one hundred microliters of specimen using the commercial Qiagen DNeasy Blood and Tissue Kit and eluted into one hundred microliters of elution buffer before storage at minus twenty degrees Celsius. The protocol then applies a multiplex polymerase chain reaction assay that amplifies two specific taxonomic markers within a single twenty-five microliter reaction mixture. The reaction combines five microliters of extracted template DNA, Phusion Plus master mix, and two customized primer pairs designated CCQ-18 and CCTZ-18, each supplied at a final concentration of zero point five micromolar.

The two primer sets target distinct conserved segments of the small subunit eighteen-S ribosomal RNA gene, designed with Primer3 software using reference sequences retrieved from the National Center for Biotechnology Information database. The CCQ-18 primer pair, comprising forward sequence GGGAGTACGTTCGCAAGAGT and reverse sequence TGTCAATCCTCACCCTGTCC, amplifies a one hundred and twenty-seven base pair amplicon specific to the family Trypanosomatidae. Concurrently, the CCTZ-18 primer pair, comprising forward sequence ACTGTGGGCCACGTAGTTTT and reverse sequence TGAGACACGAAACACCGACC, generates a three hundred and twenty-seven base pair amplicon restricted to the subgenus Trypanozoon. Amplification is carried out using an Eppendorf Mastercycler thermocycler through an initial denaturation at ninety-eight degrees Celsius for ten seconds, followed by thirty-five cycles of denaturation at ninety-eight degrees Celsius for ten seconds, annealing at sixty degrees Celsius for fifteen seconds, and extension at seventy-two degrees Celsius for thirty seconds, concluding with a ten-minute final extension at seventy-two degrees Celsius.

Separation of amplification products by one percent agarose gel electrophoresis alongside a one-kilobase DNA ladder enables direct visual resolution of the two diagnostic bands. In experimental evaluations using serial tenfold dilutions of counted Trypanosoma brucei brucei parasites ranging from one million down to one parasite per milliliter, the multiplex assay demonstrated an analytical detection limit of ten parasites per milliliter for both target sequences. In silico specificity assessments through Primer-BLAST and experimental confirmation by Sanger sequencing verified that the assay reliably distinguishes general trypanosomatid parasites from members of the Trypanozoon group, which includes human-infective trypanosomes, without non-target cross-amplification.

By conducting simultaneous amplification in one tube, the multiplex format reduces reagent consumption, consumable waste, and technical labor compared with performing distinct singleplex assays for each genetic locus. This dual-target design allows surveillance teams to establish whether an infection is caused by a member of the Trypanosomatidae family while determining at the same time whether it belongs to the Trypanozoon taxon relevant to sleeping sickness in human blood, where non-human animal trypanosomes like Trypanosoma brucei brucei are naturally lysed by human serum. Moreover, the workflow allows field teams to collect specimens and conduct initial antibody testing locally, batching only confirmed seropositive samples for shipment to centralized reference facilities equipped with thermal cyclers, gel documentation systems, and molecular expertise.

The authors highlight several operational limitations inherent to this tiered design. Because molecular analysis is strictly restricted to seropositive specimens, the algorithm will not detect infected individuals during very early stages of disease before detectable antibody titers develop, nor will it capture individuals with atypical, weak, or absent immune responses. Additionally, while the molecular phase effectively rules out false positives caused by lingering antibodies or cross-reactivity with malaria, the overall performance of the system in routine public health practice remains dependent on continuous cold chains, dependable electrical supplies, sustainable funding, and trained personnel. Nevertheless, the stratified protocol offers a standardized, practical diagnostic framework to enhance case detection and epidemiological monitoring as endemic countries work toward the targeted elimination of human African trypanosomiasis.

Subject of Research: Diagnostic protocol for human African trypanosomiasis surveillance

Article Title: An integrated serological and molecular diagnostic approach for human African trypanosomiasis screening and surveillance in low-resource and low-prevalence settings

Article References: Chukwudi, C., Chinwendu, J., Iyi, C., & Anika, S. (2026). An integrated serological and molecular diagnostic approach for human African trypanosomiasis screening and surveillance in low-resource and low-prevalence settings. Frontiers in Tropical Diseases, 7, 1956133. https://doi.org/10.3389/fitd.2026.1956133

Image Credits: AI Generated

DOI: 10.3389/fitd.2026.1956133

Keywords: Human African trypanosomiasis, Sleeping sickness, Trypanosoma brucei gambiense, Disease surveillance, Neglected tropical diseases, Multiplex PCR, ELISA, CATT, Diagnostic workflow, Low-prevalence settings, Molecular diagnostics, Trypanosomatidae, Trypanozoon, Parasite detection, Low-resource settings, Public health surveillance

News Source: Ophelia Keating. (November 19, 2026). Tiered Serological and Multiplex PCR Protocol Improves Sleeping Sickness Screening in Low-Prevalence Settings. Scienmag.

Tags: CATTdiagnostic workflowdisease surveillanceELISAhuman African trypanosomiasisLow-prevalence settingslow-resource settingsMolecular diagnosticsMultiplex PCRneglected tropical diseasesParasite detectionpublic health surveillancesleeping sicknessTrypanosoma brucei gambienseTrypanosomatidaeTrypanozoon
Share12Tweet7Share2ShareShareShare1

Related Posts

Decade Study Tracks Incarceration and Injecting Risk Among Melbourne Drug Users

Decade Study Tracks Incarceration and Injecting Risk Among Melbourne Drug Users

November 19, 2026
Three Common ACL Reconstruction Autografts Deliver Similar Clinical Outcomes in Trials

Three Common ACL Reconstruction Autografts Deliver Similar Clinical Outcomes in Trials

November 19, 2026

Medical Pharmacology Education Faces Strains From Compressed Curricula and Artificial Intelligence

November 19, 2026

Rare Anterior Mediastinal Epidermal Inclusion Cyst Mimicked Thymic Cyst in Young Woman

November 19, 2026

POPULAR NEWS

  • Survey Shows Public Awareness Remains Low as U.S. Mpox Cases Persist

    Survey Shows Public Awareness Remains Low as U.S. Mpox Cases Persist

    29 shares
    Share 12 Tweet 7
  • Single Meningococcal Conjugate Dose Demonstrates Strong Immunity Across Age Groups in Vietnam

    29 shares
    Share 12 Tweet 7
  • German Preventive Health Economic Evaluations Often Rely on Foreign Data Sources

    29 shares
    Share 12 Tweet 7
  • Virtual Community of Practice Strengthens Ukrainian Trauma Care Training During Armed Conflict

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Decade Study Tracks Incarceration and Injecting Risk Among Melbourne Drug Users

Review Maps Language and Perception Models in Home Service Robotics

Three Common ACL Reconstruction Autografts Deliver Similar Clinical Outcomes in Trials

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.